Ziegler Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Ziegler Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$9.76M	Buy	133,567 +83,144	+165%	+$6.13M	0.37%	87
2023 Q4	$3.6M	Sell	50,423 -72,735	-59%	-$4.29M	0.16%	150
2023 Q3	$7.38M	Sell	123,158 -14,546	-11%	-$957K	0.3%	121
2023 Q2	$9.93M	Buy	137,704 +30,018	+28%	+$2.25M	0.38%	88
2023 Q1	$7.92M	Buy	+107,686	New	+$7.66M	0.31%	120

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ziegler Capital Management's LGND Position: Q1 2024 in Review

Ziegler Capital Management increased its Ligand Pharmaceuticals (LGND) stake by 165% in Q1 2024, buying an estimated $6.13M and bringing the position to 133,567 shares worth $9.76M. The position accounts for 0.37% of the portfolio, ranked #87.

Ziegler Capital Management first reported a position in LGND in Q1 2023 and has held it in 5 quarters since. The position peaked at $9.93M in Q2 2023. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

Ziegler Capital Management held 133,567 shares of Ligand Pharmaceuticals worth $9.76M as of Q1 2024.
Ziegler Capital Management bought 83,144 Ligand Pharmaceuticals shares in Q1 2024, an estimated $6.13M.
Ligand Pharmaceuticals made up 0.37% of Ziegler Capital Management's portfolio in Q1 2024, its #87 holding.
Ziegler Capital Management first reported a position in Ligand Pharmaceuticals in Q1 2023 and has held it in 5 quarters since.
Ziegler Capital Management's Ligand Pharmaceuticals position peaked at $9.93M in Q2 2023.
222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on Ziegler Capital Management's 13F filing for Q1 2024, filed 15 May 2024.